Business Context and Reporting Period
Company: Spherix Incorporated (Note: Input metadata listed "Dominari Holdings Inc.", but the filing text identifies the registrant as Spherix Incorporated).
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: Spherix operates two segments: Biospherics, which develops proprietary products (primarily D-tagatose for diabetes and triglyceride treatment), and Health Sciences, which provides technical and regulatory consulting. The company is a smaller reporting company and a shell company is not applicable.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2010 | Nine Months Ended Sept 30, 2010 | Sept 30, 2010 Balance Sheet |
|---|---|---|---|
| Revenue | $368,838 | $1,028,268 | N/A |
| Net Loss | $(2,139,443) | $(6,844,930) | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.40) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2,866,832 |
| Total Assets | N/A | N/A | $3,506,129 |
| Total Liabilities | N/A | N/A | $3,042,099 |
| Stockholders' Equity | N/A | N/A | $464,030 |
| Net Cash Used in Operating Activities | N/A | $(6,534,173) | N/A |
Margins: The company operates at a significant loss. Gross margin is not explicitly stated but direct costs were $121,841 (3-month) and $353,740 (9-month) against revenue, indicating a gross profit of approximately 67% for the three-month period. However, operating expenses (R&D and SG&A) far exceed gross profit, resulting in a negative operating margin.
Material Changes vs. Prior Period
- Revenue: Revenue decreased slightly year-over-year. For the nine months ended Sept 30, 2010, revenue was $1,028,268 compared to $1,071,276 in the prior year period. All revenue is derived from the Health Sciences segment; the Biospherics segment generated no revenue.
- Net Loss: Net loss increased to $(6,844,930) for the nine months ended Sept 30, 2010, compared to $(5,772,780) in the prior year. The three-month loss remained relatively flat at $(2,139,443) vs $(2,152,156).
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by approximately 35% ($830,000) for the nine-month period compared to the prior year, driven by expanded commercialization efforts for D-tagatose. R&D expenses increased slightly to $4,310,471 (9-month) from $4,130,633.
- Liquidity: Cash and cash equivalents decreased significantly from $9,026,002 at Dec 31, 2009, to $2,866,832 at Sept 30, 2010, due to substantial development costs.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Capital Needs: The company expects to expend approximately $6 million over the next 12 months to support development operations. It anticipates needing to raise additional funds consistently to continue operations and pursue the triglyceride opportunity.
- Strategic Shift: Following a Phase 3 trial for Type 2 diabetes, the company is actively seeking a pharma partner to continue diabetes development. Simultaneously, it is shifting R&D focus to developing D-tagatose as a treatment for high triglycerides, with pre-clinical trials expected to begin in Q4 2010.
- Recent Financing: In October 2010 (subsequent to the reporting period), the company obtained net proceeds of approximately $4.9 million in a registered offering. This restored compliance with NASDAQ minimum shareholder equity requirements, which had been breached at Sept 30, 2010 (equity was $0.5 million vs. the $2.5 million requirement).
- Government Grant: In November 2010, the company was awarded $469,000 in grants from the U.S. Government under the Patient Protection and Affordable Care Act.
Risks and Contingencies
- Liquidity Risk: As of Sept 30, 2010, the company had approximately $2.9 million in cash and expected to expend this amount within six months. Continued operations depend on successful fundraising.
- Development Risk: There is no assurance that a strategic partner will be found for the diabetes drug or that the triglyceride drug will succeed in clinical trials. The triglyceride program is in early stages and could take 3-6 years to reach a partner-ready stage.
- Regulatory Risk: FDA approval is not guaranteed. The company has never filed a New Drug Application (NDA). Patent protection for the diabetes use expires in 2012.
- Delisting Risk: While the October 2010 offering restored equity compliance, the stock price fell below the $1.00 minimum bid price requirement post-offering. The company may need to implement a reverse stock split to avoid delisting from NASDAQ.
Investor Verification Checklist
- Capital Runway: Verify the status of the October 2010 $4.9 million offering and whether the $6 million 12-month burn rate estimate remains accurate given the new cash infusion.
- Partnership Progress: Confirm if a strategic partner has been secured for the D-tagatose diabetes application, as the company has scaled back internal development in this area.
- Triglyceride Trial Timeline: Monitor the initiation of pre-clinical trials for the triglyceride indication scheduled for Q4 2010 and subsequent human trial enrollment.
- NASDAQ Compliance: Check current stock price to ensure compliance with the $1.00 minimum bid price requirement and monitor for any reverse stock split announcements.
- Grant Utilization: Verify the receipt and utilization of the $469,000 U.S. Government grant awarded in November 2010.